Stay updated with breaking news from Jeff Castelli. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript February 28, 2024 Amicus Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics’ Full Year 2023 Financial Results Conference […]
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' Full Year 2023 Financial Results Conference Call and Webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) – Zacks Research decreased their Q3 2024 earnings estimates for shares of Amicus Therapeutics in a report issued on Thursday, January 18th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.00 per share for the quarter, down from their prior estimate of $0.01. […]
On December 28, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 17,421 shares of the company's stock, according to a recent SEC Filing.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript November 8, 2023 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.08. Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Third Quarter 2023 Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being […]